Syngene International, a subsidiary of Biocon has opened  a new R&D facility for its client Bristol Myers Squibb. This unit built on 200000 sq.feet has currently 270 researchers and has plans to increase it to 360 by year end and will carry out drug discovery and development from initial hit to optimisation to clinical studies.